Suchergebnisse - "Xu, Binghe"

PubPharm (9)

1

Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer : A prospective study

enthalten in: Thoracic cancer | 2024

von Wu, Y. | Mo, H. | Xu, H. | +4

2

Prognostic value and relapse pattern of HER2-low in hormone receptor-positive breast cancer

enthalten in: Thoracic cancer | 2024

von Wei, T. | Kang, Y. | Wang, X. | +3

3

Efficacy of everolimus-based therapy in advanced triple-positive breast cancer : Experience from three cancer centers in China

enthalten in: Thoracic cancer | 2023

von Tan, Y. | Jiang, H. | Ma, F. | +7

4

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer

enthalten in: Thoracic cancer | 2023

von Chai, Y. | Liu, J. | Jiang, M. | +8

5

Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites : A population-based study in patients with breast cancer

enthalten in: Thoracic cancer | 2023

von Chai, Y. | Chen, Y. | Liu, J. | +4

6

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody

enthalten in: Thoracic cancer | 2019

von Wang, X. | Zhang, B. | Chen, X. | +6

7

Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor

enthalten in: Thoracic cancer | 2018

von Wang, J. | Han, Y. | Shi, X. | +10

8

Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer

enthalten in: Thoracic cancer | 2018

von Zhai, X. | Hong, R. | Fan, Y. | +8

9

Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients

enthalten in: Thoracic cancer | 2017

von Wang, J. | Chen, S. | Xu, B. | +8

1
[1]